MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC

Published Date: 13 Sep 2024

Absolute improvement of almost 30%, doubling of duration of response with savolitinib

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

No PFS Benefit With Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma

2.

Cancer detection recovered following pandemic disruptions

3.

The Predictive Power of Liquid Biopsy in Colon Cancer Outcomes Is Inconsistent.

4.

After targeted agents, a novel bispecific in EGFR-mutant lung cancer improves PFS.

5.

Celebrity Cancers Stoking Fear? Cisplatin Shortage Ends; Setback for Anti-TIGIT


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot